Table 1. Clinicopathological characteristics.
| Characteristics | Number of patients | Percentage |
|---|---|---|
| Gender | ||
| Male | 340 | 75.2% |
| Female | 112 | 24.8% |
| Age | ||
| < 65 | 292 | 64.6% |
| ≥ 65 | 160 | 35.4% |
| ECOG PS | ||
| 0–1 | 357 | 79.0% |
| 2–3 | 95 | 21.0% |
| Smoking Status | ||
| Yes | 322 | 71.2% |
| No | 130 | 28.8% |
| Smoking packs | ||
| ≥ 30 packs-year | 278 | 86.3% |
| < 30 packs-year | 44 | 13.7% |
| Treatment modality | ||
| Chemoradiotherapy | 373 | 82.5% |
| Chemotherapy alone | 79 | 17.5% |
| Chemoradiotherapy | ||
| Concurrent | 303 | 81.2% |
| Sequential | 70 | 18.8% |
| Treatment regimen | ||
| Etoposide + platinum | 376 | 83.2% |
| Irinotecan + platinum | 76 | 16.8% |
| Chemotherapy cycles | ||
| N ≥ 4 | 396 | 87.6% |
| N < 4 | 56 | 12.4% |
| Therapy response | ||
| CR + PR | 315 | 69.6% |
| SD + PD | 137 | 30.3% |
| WBC | ||
| Normal (< 10/nl) | 302 | 70.9% |
| Elevated (≥ 10/nl) | 124 | 29.1% |
| LDH | ||
| Normal (< 240 U/l) | 299 | 69.1% |
| Elevated (≥ 240 U/l) | 134 | 30.9% |
| Hemoglobin | ||
| Nomal (≥ 110 g/l) | 342 | 85.7% |
| Decreased (< 110 g/l) | 57 | 14.3% |
| Na | ||
| Normal (≥ 135 mM) | 339 | 76.5% |
| Decreased (< 135 mM) | 104 | 23.5% |
| GLUT | ||
| Normal | 265 | 66.4% |
| Elevated | 134 | 33.6% |
| PLT | ||
| Inside (100–300*109/l) | 339 | 77.9% |
| Outside (> 300*109/L) | 96 | 22.1% |
Abbreviations: ECOG PS: Eastern Cooperative Oncology Group performance status; CR: complete response; PR: partial response; SD: disease stable; PD: disease progression; WBC: white blood count; LDH: lactate dehydrogenase; Na: sodium; GLUT: γ-glutamyl transferase; PLT: platelet count.